[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

December 2018 - April 2015

Decade

Year

Issue

January 2018, Vol 4, No. 1, Pages 1-139

Original Investigation

Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score–Matched Analysis

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):31-38. doi:10.1001/jamaoncol.2017.2805

This propensity score–matched analysis uses National Cancer Database data on patients with gastroesophageal adenocarcinoma who received preoperative chemoradiotherapy and resection to explore whether adjuvant chemotherapy confers a survival benefit compared with observation.

Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):40-47. doi:10.1001/jamaoncol.2017.2303

This phase 2 clinical trial evaluated the safety and efficacy of individualized adaptive stereotactic body radiotherapy for liver tumors in patients who have preexisting liver dysfunction.

Change in Pattern of Secondary Cancers After Kaposi Sarcoma in the Era of Antiretroviral Therapy

Abstract Full Text
free access has active quiz
JAMA Oncol. 2018;4(1):48-53. doi:10.1001/jamaoncol.2017.2395

This longitudinal study tests the hypothesis that the secondary cancers developing in patients with Kaposi sarcoma have changed in recent years and assesses the risk of secondary cancers after Kaposi sarcoma in different periods using the Surveillance, Epidemiology, and End Results (SEER) program data.

HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):54-62. doi:10.1001/jamaoncol.2017.2656

This multicenter clinical study evaluates outcomes in different age groups among older patients with de novo acute myeloid leukemia who received HLA-mismatched microtransplant.

Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):63-70. doi:10.1001/jamaoncol.2017.2752

This SEER-Medicare database study of patients with colorectal, breast, prostate, or bladder cancer compares mortality between those who began therapy with statins within 6 months after cancer diagnosis and those who did not by emulating a trial free of selection bias.

Fiber Intake and Survival After Colorectal Cancer Diagnosis

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):71-79. doi:10.1001/jamaoncol.2017.3684

This cohort study evaluates the effect of fiber intake after diagnosis on survival of patients with colorectal cancer.

Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non–Small Cell Lung Cancer After Resection With Curative Intent

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):80-87. doi:10.1001/jamaoncol.2017.2993

This study determines whether survival was affected by more stringent definitions of pathologic nodal staging quality in a cohort of patients with non–small cell lung cancer who underwent resection with curative intent.

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

Abstract Full Text
open access online only
JAMA Oncol. 2018;4(1):e173470. doi:10.1001/jamaoncol.2017.3470

This study determines whether 70-gene signature assay findings are associated with physicians’ adjuvant treatment recommendations among patients with early breast cancer.

Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(1):e173501. doi:10.1001/jamaoncol.2017.3501

This phase 2 randomized clinical trial examines whether intervening with noninvasive stereotactic ablative radiotherapy prior to maintenance chemotherapy in patients with nonprogressive limited metastatic non–small-cell lung cancer after induction therapy led to significant improvements in progression-free survival.

Brief Report

Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):89-92. doi:10.1001/jamaoncol.2017.1879

This cohort study compares rates of adverse pathologic findings among very low-risk, low-risk, and low-volume intermediate-risk men electing immediate radical prostatectomy and evaluates criteria to define if a favorable intermediate-risk group minimizing risk exists.

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):93-97. doi:10.1001/jamaoncol.2017.1617

This clinical trial of pembrolizumab in combination with metronomic cyclophosphamide assesses the efficacy and safety of PD-1 targeting in combination with metronomic chemotherapy in sarcomas.

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):98-101. doi:10.1001/jamaoncol.2017.2391

This study addressed toxic effects and time to treatment failure in patients with melanoma treated with nivolumab plus ipilimumab.

Research Letter

Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):120-122. doi:10.1001/jamaoncol.2017.2844

This study uses data from the Veterans Affairs database to examine the association of HIV status with outcomes in patients with anal cancer.

Changes in Insurance Coverage Among Cancer Patients Under the Affordable Care Act

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):122-124. doi:10.1001/jamaoncol.2017.3176

This analysis uses SEER Medicaid data to quantify changes in health insurance coverage under the Affordable Care Act among nonelderly patients newly diagnosed with cancer.

Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel–Lindau Disease

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):124-126. doi:10.1001/jamaoncol.2017.3428

This study evaluates the natural history of von Hippel–Lindau disease–associated pancreatic lesions to determine the factors associated with pancreatic neuroendocrine tumor phenotype and prognosis.

Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):126-128. doi:10.1001/jamaoncol.2017.3462

This study uses data from the National Cancer Database to examine the population-level efficacy of novel therapies for advanced-stage melanoma.

Trends in Breast, Colorectal, and Cervical Cancer Incidence Following the Affordable Care Act: Implications for Cancer Screening

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):128-129. doi:10.1001/jamaoncol.2017.3861

This observational study uses incidence rates before and after adoption of the Affordable Care Act (ACA) to assess whether adoption of the ACA increased screening for breast, colorectal, and cervical cancer.

Review

Interventions to Improve Oral Chemotherapy Safety and Quality: A Systematic Review

Abstract Full Text
JAMA Oncol. 2018;4(1):105-117. doi:10.1001/jamaoncol.2017.0625

This systematic review evaluates studies of oral chemotherapy safety and quality interventions.

JAMA Oncology Clinical Challenge

Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma

Abstract Full Text
JAMA Oncol. 2018;4(1):118-119. doi:10.1001/jamaoncol.2017.2720

A woman in her 50s receiving therapy for mantle cell lymphoma presented to the emergency department with acute, severe, left flank pain. What is your diagnosis?

Viewpoint

Rethinking Extended Adjuvant Antiestrogen Therapy to Increase Survivorship in Breast Cancer

Abstract Full Text
JAMA Oncol. 2018;4(1):15-16. doi:10.1001/jamaoncol.2017.3510

This Viewpoint discusses the potential for reducing recurrence and mortality in patients with high-risk estrogen receptor–positive breast cancer by using an affordable intermittent salvage therapy.

Pemetrexed in Nonsquamous Non–Small Cell Lung Cancer: The Billion Dollar Subgroup Analysis

Abstract Full Text
JAMA Oncol. 2018;4(1):17-18. doi:10.1001/jamaoncol.2017.1944

This Viewpoint explores the possibility that data from published trials have been used to bolster the sales of a pemetrexed for use in nonsquamous non–small cell lung cancer.

Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2018;4(1):19-20. doi:10.1001/jamaoncol.2017.3323

This Viewpoint examines consideration of human epidermal growth factor receptor 2 as a biomarker in metastatic CRC.

Invited Commentary

Quality of Lymph Node Assessment and Survival Among Patients With Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2018;4(1):1-2. doi:10.1001/jamaoncol.2017.3092

Adjuvant Chemotherapy Following Neoadjuvant Chemotherapy Plus Surgery for Patients With Gastroesophageal Cancer—Is There Room for Improvement?

Abstract Full Text
JAMA Oncol. 2018;4(1):38-39. doi:10.1001/jamaoncol.2017.2792
JAMA Oncology Patient Page

Complementary and Alternative Medicine in Cancer Care

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):139. doi:10.1001/jamaoncol.2017.3120
Cancer Care Chronicles

The Floor Is Not Stable

Abstract Full Text
JAMA Oncol. 2018;4(1):21-22. doi:10.1001/jamaoncol.2017.2847

This article provides a perspective on the effect of a diagnosis of cancer.

RAISE Act or Reduce Act?

Abstract Full Text
JAMA Oncol. 2018;4(1):23-24. doi:10.1001/jamaoncol.2017.3766
Poetry and Oncology

Mise en Place

Abstract Full Text
JAMA Oncol. 2018;4(1):134. doi:10.1001/jamaoncol.2017.2455
Comment & Response

Validity of Surrogate End Points for Prostate Cancer

Abstract Full Text
JAMA Oncol. 2018;4(1):129-130. doi:10.1001/jamaoncol.2017.0334

Validity of Surrogate End Points for Prostate Cancer—Reply

Abstract Full Text
JAMA Oncol. 2018;4(1):130-131. doi:10.1001/jamaoncol.2017.2506

Timing of Pregnancy and Survival in Women With Breast Cancer

Abstract Full Text
JAMA Oncol. 2018;4(1):131. doi:10.1001/jamaoncol.2017.2711

Is There Merit for MET-Targeted Therapies in Gastroesophageal Cancer?

Abstract Full Text
JAMA Oncol. 2018;4(1):131-132. doi:10.1001/jamaoncol.2017.2725

Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors

Abstract Full Text
JAMA Oncol. 2018;4(1):132. doi:10.1001/jamaoncol.2017.2802

Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors—Reply

Abstract Full Text
JAMA Oncol. 2018;4(1):132-133. doi:10.1001/jamaoncol.2017.2813
Correction

Errors in Table

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):133. doi:10.1001/jamaoncol.2017.3889

Open Access Information Added

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):133. doi:10.1001/jamaoncol.2017.4703
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):6. doi:10.1001/jamaoncol.2017.1718
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2018;4(1):3. doi:10.1001/jamaoncol.2017.1717
×